Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis

Diabetic nephropathy (DN) is one of the most serious microvascular complications of diabetes, valsartan and α-lipoic acid alone or in combination has been used for the treatment of patients with DN. However, some results in these clinical reports were still controversial. The purpose of this study w...

Full description

Saved in:
Bibliographic Details
Published in:BMC endocrine disorders 2021-08, Vol.21 (1), p.178-178, Article 178
Main Authors: Sun, Fangfang, Jiang, Deqi, Cai, Juanjuan
Format: Article
Language:English
Subjects:
Acids
Albumin
Antihypertensive Agents - therapeutic use
Antioxidants
Antioxidants - therapeutic use
C-reactive protein
Clinical outcomes
Clinical trials
Cytokines
Diabetes
Diabetes mellitus
Diabetic Nephropathies - drug therapy
Diabetic Nephropathies - pathology
Diabetic nephropathy
Disease
Drug dosages
Drug Therapy, Combination
Extracellular matrix
Glucose
Growth factors
Humans
Hyperglycemia
Kidney - drug effects
Kidney - physiology
Kinases
Lipoic acid
Meta-analysis
Microvasculature
Nephropathy
Oxidative stress
Patients
Proteins
Renal function
Thioctic Acid - therapeutic use
Valsartan
Valsartan - therapeutic use
α-Lipoic acid
β2 Microglobulin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetic nephropathy (DN) is one of the most serious microvascular complications of diabetes, valsartan and α-lipoic acid alone or in combination has been used for the treatment of patients with DN. However, some results in these clinical reports were still controversial. The purpose of this study was to evaluate the efficacy of valsartan combined with α-lipoic acid on renal function in patients with DN. We searched the electronic databases including PubMed, Sciencedirect, EMBASE, Cochrane library, Chinese national knowledge infrastructure (CNKI) and Wanfang databases, and the publication deadline was limited to January 2020. Randomized controlled trials (RCTs) evaluating the effects of valsartan combined with α-lipoic acid in DN patients were included. Pooled estimates were conducted using a fixed or random effect model. The outcomes included urinary albumin excretion rate (UAER), and the level of urinary albumin, β -microglobulin (β -MG), hypersensitive C-reactive protein (hs-CRP) and oxidative stress. 11 studies with 1294 participants were included in this study. The pooled analysis indicated that α-lipoic acid combined with valsartan could remarkably reduce UAER (P 
ISSN:1472-6823
1472-6823
DOI:10.1186/s12902-021-00844-0